Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip
Phase 4
Completed
- Conditions
- Osteoarthritis, Hip
- Registration Number
- NCT00174317
- Lead Sponsor
- Pfizer
- Brief Summary
To determine if celecoxib 200 mg once daily is as effective as diclofenac 50 mg three times daily in the treatment of pain symptoms associated with osteoarthritis of the hip
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
- Diagnosed with osteoarthritis of hip and requiring joint replacement
- Eligible for chronic therapy with an NSAID
Exclusion Criteria
- Hip surgery anticipated within 8 calendar weeks after first visit
- Active gastrointestinal disease or recent diagnosis of gastrointestinal ulceration (within 60 days of first visit)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change in patient assessment of arthritis pain on walking VAS (Visual Analog Scale) as measured on a 0-100 mm scale at week 6 compared to baseline
- Secondary Outcome Measures
Name Time Method Change in patient assessment of arthritis pain on walking VAS (Visual Analog Scale) as measured on a 0-100 mm scale at week 12 compared to baseline. Change in patients global assessment of arthritis between treatment groups.
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇬🇧Wigan, United Kingdom